论文部分内容阅读
目的：观察ＶＭ２６并ＢＣＮＵ静滴治疗恶性脑瘤的临床疗效。方法：对５６例脑瘤于手术切除后，采用超选脑动脉灌注ＶＭ２６并静滴ＢＣＮＵ，在治疗前后分别比较肿瘤体积变化及临床症状。结果：化疗前肿瘤平均体积为１５．１±７．３３ｃｍ３，化疗后平均体积为８．１１±８．９２ｃｍ３（Ｐ＜０．０１），总的有效率为６７．８％（３８／５６），完全缓解率为２１．４％（１２／５６）。本组病例１年存活率达７３．２％，２年存活率为４１．１％，全部患者均无眼部症状及严重的药物神经毒性反应。结论：超选脑动脉灌注和静滴联合化疗法，较单纯颈内动脉灌注及外周静脉化疗存活率高，而且并发症少，全身反应轻。
Objective: To observe the clinical effect of intravenous infusion of VM26 and BCNU on malignant brain tumor. Methods: After 56 cases of brain tumor were surgically resected, VM26 was intravenously infused with intravenous infusion of BCNU, and the changes of tumor volume and clinical symptoms were compared before and after treatment. Results: The average volume of tumor before chemotherapy was 15.1 ± 7.33cm3 and the average volume after chemotherapy was 8.11 ± 8.92cm3 (P <0.01). The total effective rate was 67.8% (38/56) The complete response rate was 21.4% (12/56). The 1-year survival rate of this group was 73.2%, 2-year survival rate was 41.1%, all patients without ocular symptoms and serious drug neurotoxic reactions. Conclusion: Superselective intracranial arterial infusion and intravenous infusion of combined chemotherapy, compared with simple internal carotid artery perfusion and peripheral vein chemotherapy, high survival rate, and fewer complications, less systemic reactions.